Filtered By:
Condition: Atrial Fibrillation
Cancer: Brain Cancers

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 58 results found since Jan 2013.

The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
Authors: Lasek-Bal A, Jedrzejowska-Szypulka H, Student S, Warsz-Wianecka A, Zareba K, Puz P, Bal W, Pawletko K, Lewin-Kowalik J Abstract Acute cerebral ischemia triggers local and systemic immune response. The aims of this project was to assess the blood serum concentration of the markers of inflammation and markers of the blood brain barrier damage on the first day of ischemic stroke, and the mutual correlations between these marker levels. Patients with first-in-life stroke were analysed according to: plasma concentration of the following markers on the first day of stroke: interleukin 2 (IL-2) and interleuki 6 (...
Source: Journal of Physiology and Pharmacology - July 31, 2019 Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research

Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study
This study includes consecutive patients 20 years and older who were newly diagnosed with symptomatic multiple myeloma at Taipei Veterans General Hospital, a tertiary medical center, between January 1, 2002 and December 31, 2014. The primary outcome was stroke development. Patients with head injuries, brain tumors, brain parenchymal invasions, or antecedent malignancies were excluded. Hazard ratios (HRs) of stroke risk factors for multiple myeloma patients were estimated by Cox proportional regression analysis. Overall, 395 patients with a median age of 70 years were investigated. In the median follow‐up period of 18 ...
Source: Hematological Oncology - August 21, 2016 Category: Hematology Authors: Gin ‐Yi Lee, Yu‐Ting Lee, Chiu‐Mei Yeh, Pei Hsu, Ting‐Wei Lin, Jyh‐Pyng Gau, Yuan‐Bin Yu, Liang‐Tsai Hsiao, Cheng‐Hwai Tzeng, Tzeon‐Jye Chiou, Jin‐Hwang Liu, Yao‐Chung Liu, Chia‐Jen Liu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

The emerging role of microRNA in stroke.
Abstract MicroRNAs (miRNAs) are small non-coding RNAs approximately 22 nucleotides in length that play a pivotal role in post-transcriptional gene regulation by binding to complementary sites in the 3'-untranslated region of messenger RNAs. In the past decade, their role in several human diseases, from cancer to cardiovascular disease, has been established by a wealth of evidence. Stroke is responsible for 10% of deaths worldwide and is one of the leading causes of disability. MiRNAs are involved in stroke risk factors including hypertension, atherosclerosis, atrial fibrillation, diabetes and dyslipidemia. The rol...
Source: Current Topics in Medicinal Chemistry - May 31, 2013 Category: Chemistry Authors: Koutsis G, Siasos G, Spengos K Tags: Curr Top Med Chem Source Type: research

Midbrain and bilateral paramedian thalamic stroke due to artery of Percheron occlusion.
CONCLUSION: Bilateral thalamic stroke due to artery of Percheron occlusion is a rare presentation of stroke, which can be overlooked in routine CT scan. If diagnosed, it requires further evaluation for stroke risk factors, especially cardiovascular disorders associated with increased embolic risk. PMID: 27154444 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - April 30, 2016 Category: Neurology Authors: Restel M, Graban A, Witkowski G, Ryglewicz D, Sienkiewicz-Jarosz H Tags: Neurol Neurochir Pol Source Type: research

Midbrain and bilateral paramedian thalamic stroke due to artery of Percheron occlusion
Conclusion Bilateral thalamic stroke due to artery of Percheron occlusion is a rare presentation of stroke, which can be overlooked in routine CT scan. If diagnosed, it requires further evaluation for stroke risk factors, especially cardiovascular disorders associated with increased embolic risk.
Source: Polish Journal of Neurology and Neurosurgery - January 26, 2016 Category: Neurosurgery Source Type: research

Intraoperative stroke in the mandibular osteoradionecrosis: A case report
Publication date: January 2015 Source:Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, Volume 27, Issue 1 Author(s): Ryo Sasaki , Chie Kagawa , Toshihiro Okamoto , Tomohiro Ando Although risk factors for perioperative stroke during head and neck surgery are known, the risk of perioperative stroke in osteoradionecrosis (ORN) patients is scarcely known. Sixty-seven-year-old male presented ORN in the mandible after 9 years docetaxel, cisplatin, and 5-fluorouracil (TPF) chemo, and 66Gy radiation therapies for the oropharynx cancer, which was diagnosed Marx's classification class II. After pre-operative hyp...
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - January 1, 2015 Category: ENT & OMF Source Type: research

Intratumoral Hemorrhage in a Patient with Malignant Meningioma under Anticoagulant Therapy
We report the case of an elderly woman with malignant meningioma and atrial fibrillation who started taking anticoagulants after an ischemic stroke and subsequently developed intratumoral hemorrhage. Further studies are required to confirm whether a particular anticoagulant agent is suitable for patients with brain tumor and atrial fibrillation.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2015 Category: Neurology Authors: Yasuyuki Ito, Makoto Nakajima, Mari Watari, Tetsuro Sakamoto, Yoichiro Hashimoto, Seiji Tajiri, Akira Takada, Yukio Ando Tags: Case Report Source Type: research

Correlation Between Intracranial Arterial Calcification and Imaging of Cerebral Small Vessel Disease
Conclusion: Intracranial artery calcification is common in patients with ischemic cerebrovascular disease and the intracranial carotid artery is most frequently affected. Intracranial arterial calcifications might be associated with imaging markers of SVD and are highly correlated with WMHs, lacunes, and CMBs. Quantification of calcification on CT provides additional information on the pathophysiology of SVD. Intracranial arterial calcification could act as a potential marker of SVD. Introduction Atherosclerosis is a systemic vascular process that is considered a major cause of cerebrovascular and cardiovascular di...
Source: Frontiers in Neurology - April 30, 2019 Category: Neurology Source Type: research

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

From cryptogenic to ESUS: Toward precision medicine?
Rev Neurol (Paris). 2022 May 18:S0035-3787(22)00592-6. doi: 10.1016/j.neurol.2022.01.016. Online ahead of print.ABSTRACTCryptogenic infarctions are infarctions without a defined cause, despite a complete work-up. They differ from infarctions of undetermined causes, which may involve overlapping causes or an incomplete investigation. It is also different from uncommon heritable and non-heritable causes. The term embolic stroke of undetermined source (ESUS) proposed in 2014 is defined as a non-lacunar brain infarct without proximal arterial stenosis or cardioembolic sources. The major advantage of this definition compared to...
Source: Revue Neurologique - May 21, 2022 Category: Neurology Authors: S Timsit Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news